Post by ICON plc

Operational and safety protocols for neurologic monoclonal antibodies (mAbs) must be precisely matched to disease biology and operational strategy, including mandatory B‑cell and infection monitoring in multiple sclerosis or precise biomarker stratification in neuromyelitis optica spectrum disorder. Discover how to build a development approach that accounts for these needs in the whitepaper. https://ow.ly/XVGF50YQVar